Understanding how hormone-dependent prostate cancer is identified and monitored is crucial for anyone facing this diagnosis. From blood tests that track disease progression to imaging scans that reveal cancer location, diagnostic methods play a vital role in guiding treatment decisions and measuring response to therapy.

Introduction: Who Needs Diagnostic Testing for Hormone-Dependent Prostate Cancer

Hormone-dependent prostate cancer, also known as hormone-sensitive prostate cancer, is a form of prostate cancer that relies on male sex hormones called androgens to grow and spread. The most abundant androgen in men is testosterone, which is primarily produced in the testicles with smaller amounts coming from the adrenal glands. In hormone-dependent prostate cancer, cancer cells grow when testosterone binds to and activates a protein called the androgen receptor found in prostate cells.^[1]

Diagnostic testing for this condition becomes important when men show signs or symptoms that could indicate prostate cancer, such as urinary difficulties, blood in urine, or unexplained weight loss. Men at higher risk—including those with a family history of prostate cancer, Black men who face higher rates of the disease, or men over age 50—should discuss screening with their healthcare provider even without symptoms. Early detection through diagnostic tests can identify the disease at a stage when it is most treatable and may still be confined to the prostate gland.^[3]

Diagnostic tests are also essential for men already diagnosed with prostate cancer. These tests help doctors determine whether the cancer is hormone-sensitive or has progressed to become castration-resistant, meaning it continues to grow even when testosterone levels are extremely low. This distinction is critically important because it determines which treatments will be most effective. Men who have been treated with hormone therapy need regular diagnostic monitoring to check how well the treatment is working and whether the cancer remains sensitive to hormone manipulation.^[1]

Classic Diagnostic Methods

Blood Tests: The Foundation of Diagnosis

The prostate-specific antigen (PSA) blood test is one of the most fundamental diagnostic tools for prostate cancer. PSA is a protein produced by the prostate gland, and elevated levels in the blood can indicate prostate cancer, though they can also result from other prostate conditions. While the PSA test alone cannot diagnose hormone-dependent prostate cancer, it serves as an important screening tool and monitoring marker. Rising PSA levels after treatment can signal that cancer is progressing or returning, which may indicate a change in how the cancer responds to hormones.^[1]

Blood tests also measure testosterone levels, which is essential for diagnosing hormone-dependent prostate cancer and monitoring treatment. Since this type of cancer depends on testosterone to grow, knowing the hormone levels in the body helps doctors understand whether the cancer is likely to respond to hormone-blocking treatments. During treatment with androgen deprivation therapy (ADT), regular blood tests confirm that testosterone levels have dropped to the desired range—typically to castration levels, which are extremely low.^[1]

Physical Examination

A digital rectal examination (DRE) is a physical test where a healthcare provider inserts a gloved, lubricated finger into the rectum to feel the prostate gland. Because the prostate sits just in front of the rectum, this allows the doctor to check for lumps, hard areas, or other abnormalities that might suggest cancer. While not definitive on its own, the DRE provides valuable information about the size, texture, and consistency of the prostate. It is often performed alongside PSA testing to provide a more complete picture of prostate health.^[4]

Imaging Studies

Various imaging techniques help visualize the prostate and detect cancer spread. Magnetic resonance imaging (MRI) scans create detailed pictures of the prostate and surrounding tissues using magnets and radio waves. This test can show the location and size of suspicious areas within the prostate without using radiation. MRI is particularly helpful in guiding biopsies to the most suspicious areas and determining whether cancer has spread beyond the prostate capsule.^[23]

Computed tomography (CT) scans use X-rays taken from different angles to create cross-sectional images of the body. These scans help determine whether prostate cancer has spread to lymph nodes, bones, or other organs. Similarly, bone scans are specialized imaging tests that can detect whether cancer has metastasized to the bones, which is a common site of spread for prostate cancer. During a bone scan, a small amount of radioactive material is injected into a vein, and areas where cancer has spread to bone will show up as bright spots on the scan images.^[23]

Positron emission tomography (PET) scans involve injecting a small amount of radioactive substance into the body, which cancer cells absorb more readily than normal cells. This creates images showing areas of increased metabolic activity that may indicate cancer. PET scans can be particularly useful for detecting prostate cancer that has spread beyond the prostate gland and may help distinguish between hormone-sensitive and castration-resistant disease.^[23]

Tissue Biopsy

A prostate biopsy is the definitive way to diagnose prostate cancer. During this procedure, a doctor removes small samples of prostate tissue using a needle, typically guided by ultrasound imaging. The tissue samples are then examined under a microscope by a pathologist who can confirm whether cancer is present and determine its characteristics. The biopsy results include important information about how aggressive the cancer appears and whether it expresses androgen receptors, which indicates it is likely hormone-dependent.^[23]

The biopsy also provides a Gleason score, which rates how abnormal the cancer cells look compared to normal prostate tissue. This scoring system helps predict how quickly the cancer might grow and spread. Higher Gleason scores generally indicate more aggressive cancers that may be more likely to become resistant to hormone therapy over time.^[5]

Diagnostics for Clinical Trial Qualification

Standard Eligibility Criteria

Clinical trials investigating new treatments for hormone-dependent prostate cancer require specific diagnostic tests to ensure participants meet eligibility criteria. These trials typically require documented evidence that the cancer is indeed hormone-sensitive, meaning it has not yet become resistant to hormone therapy. This is usually confirmed through PSA testing showing that the cancer initially responds to testosterone reduction, combined with relatively recent diagnosis or disease progression while testosterone levels remain normal or elevated.^[1]

Many clinical trials for metastatic hormone-sensitive prostate cancer require imaging studies to confirm the extent of disease spread. Participants often need CT scans, bone scans, or more advanced PET imaging to document whether cancer has spread to lymph nodes, bones, or other organs. These baseline scans serve two purposes: they help determine trial eligibility and provide a starting point for measuring whether experimental treatments are working.^[13]

Hormone Level Documentation

Clinical trials frequently require baseline testosterone measurements to establish that the cancer is growing in an environment where testosterone is present. For trials testing new hormone therapies or combinations of treatments, investigators need to know the starting testosterone level to properly assess how well the experimental therapy reduces hormones. Some trials also measure other androgens beyond testosterone, including dihydrotestosterone (DHT), which has an even stronger binding affinity for the androgen receptor than testosterone itself.^[1]

Disease Staging and Risk Classification

Trials often enroll patients based on specific disease stages or risk categories. Standard staging evaluations include the combination of PSA level, Gleason score from biopsy, and clinical stage determined by physical examination and imaging. These factors classify patients into risk groups such as low-risk, intermediate-risk, or high-risk hormone-sensitive prostate cancer. High-risk disease features might include high PSA levels, high Gleason scores, or evidence of cancer spread beyond the prostate, and such patients may be eligible for trials testing more intensive treatment combinations.^[13]

For trials enrolling patients with metastatic hormone-sensitive prostate cancer, additional classification may separate patients into those with high-volume disease (extensive spread to multiple sites) versus low-volume disease (limited spread). This classification typically requires bone scans and CT imaging to count and locate cancer lesions. The volume and location of metastatic disease can influence both trial eligibility and treatment approaches being studied.^[12]

Genetic and Molecular Testing

Some advanced clinical trials now include genetic testing of tumor tissue to identify specific molecular characteristics that might predict treatment response. These tests look for mutations in genes related to DNA repair, hormone receptor function, or other cellular processes. While not yet standard for all hormone-dependent prostate cancer cases, molecular profiling is increasingly used in research settings to match patients with targeted therapies that might work best for their specific cancer biology.^[3]

Monitoring Tests During Trials

Once enrolled in a clinical trial, participants undergo regular diagnostic monitoring to assess treatment response and detect side effects. PSA testing occurs at frequent intervals—often monthly or every few months—to track whether the cancer is responding to treatment. Testosterone levels are measured regularly in trials of hormone therapies to confirm the drugs are achieving their intended biochemical effect of reducing androgen levels.^[1]

Repeat imaging studies at scheduled intervals document whether tumors are shrinking, staying stable, or growing. These might include the same types of scans performed at trial entry, allowing direct comparison. Blood tests monitoring general health—including kidney function, liver function, and blood cell counts—help detect potential side effects from experimental treatments. Some trials also include quality of life questionnaires as a form of diagnostic assessment, measuring how treatments affect daily functioning and symptom burden.^[19]